GRAMMY® Award winner and the national spokesperson for EUFLEXXA® (1 percent sodium hyaluronate), Gloria Gaynor has partnered with Ferring Pharmaceuticals Inc. to launch a five-part exercise video series that encourages people with pain due to osteoarthritis (OA) of the knee to maintain healthy, active lifestyles.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/euflexxa/49736/
As the rate of teen prescription drug abuse continues to rise in the United States, the National Association of School Nurses (NASN) and Janssen Pharmaceuticals, Inc., today joined with addiction expert Dr. Drew Pinsky,* to launch a new tool kit intended to help America’s schools educate teens and their parents about the risks and consequences of abusing prescription medication.
The Schools Get Smart, Schools Take Action Tool Kit is part of Smart Moves, Smart Choices, a national initiative of NASN and Janssen Pharmaceuticals, Inc., designed to inform parents, teens and educators about this growing problem of teen prescription drug abuse, and what they can do to combat it.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/smartmovessmartchoices/51444/
With the flip of a switch on Thursday, the largest solar panel array in New Jersey will come to life on the campus of Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., as company leaders and employees inaugurate the largest solar installation of any site among the Johnson & Johnson Family of Companies around the world.
To view Multimedia News Release, go to http://multivu.pACrnewswire.com/mnr/janssen/45911/
Boehringer Ingelheim Pharmaceuticals, Inc. y la Comisión Latina sobre el SIDA anunciaron hoy el lanzamiento del sitio web Mente, Cuerpo, HAART™ (MenteCuerpoHAART.com), un recurso en línea en español para los latinos que viven con el VIH, para proveedores de servicios de salud y para educadores de la salud. El sitio ofrece herramientas y consejos útiles sobre cómo mantener el bienestar mental, físico y emocional ante los desafíos diarios de la enfermedad.
Para ver más comunicado de prensa multimedios, visite http://multivu.prnewswire.com/mnr/boehringeringelheim/46494/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/pvct/43978/
Boehringer Ingelheim Pharmaceuticals, Inc. and CancerCare® today announced the launch of My Cancer Circle™ (www.MyCancerCircle.net), a free, private, customizable online tool that enables caregivers of people facing cancer to organize and coordinate a circle of family members and friends to provide practical and emotional support. MyCancerCircle.net will provide caregivers of people facing cancer a simple, effective answer to a question they are asked constantly, “What can we do to help?”
To view Multimedia News Release, go to http://www.multivu.com/mnr/56339-boehringer-ingelheim-cancercare-my-cancer-circle-online-tool-caregivers
After an unexpected diagnosis of atrial fibrillation (AFib), a type of irregular heart beat they had never heard of before, daytime TV star Susan Lucci and her husband Helmut Huber learned he is one of the estimated 2.3 million Americans living with the condition, which can increase the risk of stroke nearly five-fold. The couple, who have spent more than a decade working with their doctor to help minimize Helmut’s stroke risk, today announced they have partnered with Boehringer Ingelheim Pharmaceuticals, Inc., National Stroke Association and StopAfib.org to launch a new national education program to improve awareness of AFib and its increased risk of stroke.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/boehringer-ingelheim/46196/
Pet owner Judy Bernath loves her 11-year-old cat Billy, so when she noticed he had become lethargic, started losing weight and drastically changed from the happy cat he had once been, she made a visit to see her veterinarian Dr. David Bruyette, medical director at VCA West Los Angeles Animal Hospital. The VCA team diagnosed Billy as being hyperthyroid within a few days, and Dr. Bruyette shared conventional therapy options with Judy, like radiation therapy, daily pharmaceuticals and surgery. In addition, he discussed and ultimately recommended a new and different approach for Billy’s case – nutritional management.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51765-hills-pet-nutrition-launches-new-pet-food-for-hyperthyroid-cats
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company’s novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI). The Phase 3 trial showed that fidaxomicin significantly reduced recurrence rates and increased global cure rates when compared to vancomycin, the only treatment approved by the U.S. Food and Drug Administration for CDI. The article titled,
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
Iroko Pharmaceuticals, LLC, a Philadelphia-based pharmaceutical company focused on the development and commercialization of innovative therapeutic products, today announced the opening of its new environmentally friendly corporate headquarters in Philadelphia’s Navy Yard Corporate Center. This milestone is part of the Company’s long-term growth plan as it advances its late-stage pipeline of lower dose submicron non-steroidal anti-inflammatory drugs (NSAIDs) towards commercialization.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58559-iroko-pharmaceuticals-opens-philadelphia-headquarters-hq
